December 11, 2013 — Compañía Mexicana de Radiología, CGR, S.A. de C.V. (CMR) acquired certain Naviscan Inc. assets, including intellectual property and the Naviscan trademark. CMR plans to continue sales and support of Naviscan’s high-resolution organ-specific positron emission tomography (PET) imaging technology.
CMR, a Mexico-based company, has been a developer and manufacturer of quality diagnostic imaging equipment and healthcare IT solutions for more than 25 years. CMR recently established a U.S.-based corporation — CMR Naviscan Corp. — that will continue to develop and manufacture Naviscan’s molecular imaging technology in Carlsbad, Calif.
“In addition to sustaining this critical technology for breast cancer patients, we will be able to provide a more comprehensive product offering to our healthcare customers,” said Tonatiuh Monroy, director general, CMR. “We are committed to retaining the high level of product quality and customer service established by Naviscan.”
The new company exhibited its products at the Radiological Society of North America Annual Meeting (RSNA 2013) in Chicago.
For more information: www.cmr-naviscan.com, www.rsna.org
April 10, 2024 
![(A) PET images of [68Ga]Ga-DOTA-ZCAM241 uptake at baseline and 3, 7, and 12 days after injection as inflammatory arthritis developed in single representative individual mouse. Images are normalized to SUV of 0.5 for direct comparison between time points. (B) CD69 immunofluorescence Sytox (Thermo Fisher Scientific) staining of joints of representative animals during matching time points.](/sites/default/files/styles/feed_medium/public/PET%20Tracers.jpeg?itok=P5Di6MIe)
